肝脂肪变性预示胃旁路术后糖尿病缓解更佳
研究纳入519例接受Roux-en-Y胃旁路术且术中行肝活检的2型糖尿病患者,随访至少5年。活检证实的肝脂肪变性患者长期糖尿病缓解率为52%(211/407),无脂肪变性者为39%(44/112),差异有统计学意义(P=0.027)。多因素分析显示肝脂肪变性是长期糖尿病缓解的独立预测因子(OR 1.96,95%CI 1.04-3.72,P=0.038)。
要点
- 肝脂肪变性是胃旁路术后长期糖尿病缓解的独立预测因子。
- 有肝脂肪变性者缓解率52%,无脂肪变性者39%。
- 肝细胞气球样变、小叶炎症或纤维化不能预测糖尿病缓解。
核心结论
- 在考虑代谢手术的2型糖尿病患者中,合并肝脂肪变性与更好的长期血糖结局相关。
- 研究提示存在对手术减重代谢反应不同的2型糖尿病亚型。
研究设计与样本
- 回顾性分析519例接受Roux-en-Y胃旁路术并同时行肝活检的2型糖尿病患者,随访至少5年。
主要发现
- 407例活检证实的肝脂肪变性患者中211例(52%)实现长期糖尿病缓解。
- 112例无肝脂肪变性患者中44例(39%)实现长期糖尿病缓解(P=0.027)。
- 多因素分析中肝脂肪变性是长期糖尿病缓解的独立预测因子(OR 1.96,95%CI 1.04-3.72,P=0.038)。
- 基线肝细胞气球样变、小叶炎症或纤维化未预测糖尿病缓解。
关键数值与推荐
- 长期糖尿病缓解定义为停用降糖药物后糖化血红蛋白<6.5%(48 mmol/mol)。
临床怎么用
- 对合并肝脂肪变性的2型糖尿病患者,胃旁路术后长期糖尿病缓解概率更高。
- 肝脂肪变性可辅助识别代谢手术获益更大的2型糖尿病亚型。
局限性
- 原文未明确报告研究设计类型(回顾性或前瞻性),仅提及分析519例患者。
- 原文未报告其他混杂因素、随访细节或样本量计算依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance (IR) and β-cell dysfunction. Ectopic fat accumulation in liver and muscle causes IR. Since bariatric and metabolic surgery significantly improves fatty liver disease, we hypothesized that coexistence of liver steatosis (i.e., when hepatic IR contributes in T2DM) would be associated with greater diabetes improvement after surgery. RESEARCH DESIGN AND METHODS: A total of 519 patients with T2DM who underwent Roux-en-Y gastric bypass and simultaneous liver biopsy and had a minimum 5-year follow-up were analyzed to assess the independent association between biopsy-proven liver steatosis and postoperative long-term diabetes remission (glycated hemoglobin <6.5% [48 mmol/mol] off medications). RESULTS: Of the 407 patients with biopsy-proven liver steatosis, long-term diabetes remission was achieved in 211 (52%) patients compared with remission in 44 out of 112 (39%) patients without steatosis (P = 0.027). In multivariable analysis, presence of liver steatosis was an independent predictor of long-term diabetes remission (odds ratio 1.96 [95% CI 1.04-3.72]; P = 0.038). Hepatocyte ballooning, lobular inflammation, or fibrosis at baseline did not predict diabetes remission. CONCLUSIONS: This study, for the first time, suggests that in patients with T2DM who are considering bariatric and metabolic surgery, coexistence of liver steatosis is associated with better long-term glycemic outcomes. Furthermore, our data suggest that there are distinct variants of T2DM in which metabolic responses to surgical weight loss are different. A subgroup of patients whose T2DM is characterized by the presence of hepatic steatosis (presumably associated with worse IR) experience better postoperative metabolic outcomes.
引用
- Vangoitsenhoven R, Wilson RL, Cherla DV, et al. Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery. Diabetes Care. 2020. PMID: 33323476. doi:10.2337/dc20-0150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。